Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 15/20 | 0.57 |
| ▸ | CDK1 | P06493 | 7/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204068 | 0.84 | TNIK (0.62) | TNIKCDK2 | |
| SCHEMBL21253108 | 0.75 | TNIK (1.00) | TNIK | |
| SCHEMBL29965901 | 0.75 | TNIK (1.00) | TNIK | |
| SCHEMBL7545155 | 0.74 | CDK2 (0.60) | CDK2CDK1CA1CA2CA9 | |
| SCHEMBL7204720 | 0.70 | CDK2 (0.47) | CDK2CDK1 | |
| SCHEMBL7639290 | 0.70 | CDK2 (0.62) | TNIKCDK2CDK1 | |
| SCHEMBL7536409 | 0.70 | CDK2 (0.60) | TNIKCDK2CDK1CA1CA2 | |
| SCHEMBL7208562 | 0.70 | CDK2 (0.72) | TNIKCDK2CDK1 | |
| SCHEMBL13953170 | 0.70 | TNIK (0.49) | TNIK | |
| SCHEMBL21247521 | 0.69 | TNIK (1.00) | TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274706-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6462069-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | AGOURON PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2001079198-A9 | PYRAZOLES FOR INHIBITING PROTEIN KINASE | AGOURON PHARMA (US) | 2002-05-16 | — | — | WO | disclosed |
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | LIGHPOINTE COMMUNICATION, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001079198-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | CDK3, CCNK, CDK1 | TNIK 304/4885CDK2 4/4885CDK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.